Larimar Therapeutics, Inc. (NASDAQ:LRMR – Free Report) – Equities researchers at Lifesci Capital issued their Q2 2025 earnings per share estimates for Larimar Therapeutics in a report released on Monday, June 23rd. Lifesci Capital analyst C. Jubinville forecasts that the company will post earnings of ($0.46) per share for the quarter. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Lifesci Capital also issued estimates for Larimar Therapeutics’ Q3 2025 earnings at ($0.46) EPS and Q4 2025 earnings at ($0.46) EPS.
Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04).
Get Our Latest Stock Report on Larimar Therapeutics
Larimar Therapeutics Trading Up 8.7%
Shares of Larimar Therapeutics stock opened at $3.25 on Wednesday. The company has a market capitalization of $208.10 million, a PE ratio of -2.18 and a beta of 0.79. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $11.20. The stock’s fifty day simple moving average is $2.37 and its 200 day simple moving average is $2.96.
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets acquired a new position in Larimar Therapeutics during the fourth quarter valued at approximately $25,000. Walleye Capital LLC acquired a new position in shares of Larimar Therapeutics during the first quarter worth $37,000. Algert Global LLC acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $47,000. Graham Capital Management L.P. acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $54,000. Finally, ProShare Advisors LLC acquired a new position in shares of Larimar Therapeutics during the fourth quarter worth $58,000. 91.92% of the stock is currently owned by institutional investors and hedge funds.
About Larimar Therapeutics
Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.
Recommended Stories
- Five stocks we like better than Larimar Therapeutics
- Why Are These Companies Considered Blue Chips?
- Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
- What is an Earnings Surprise?
- Uber and Tesla Surge on Robotaxis, Analyst Touts Texas Rides
- Investing in Construction Stocks
- ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Receive News & Ratings for Larimar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Larimar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.